中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
23期
14-15,16
,共3页
孟鲁司特钠%脾氨肽%哮喘%细胞因子%肺功能
孟魯司特鈉%脾氨肽%哮喘%細胞因子%肺功能
맹로사특납%비안태%효천%세포인자%폐공능
Montelukast%Spleen aminopeptide%Asthma%Cytokines%Lung function
目的：观察孟鲁斯特钠联合脾氨肽对哮喘患儿Th1/Th2细胞因子的影响及临床疗效。方法106例支气管哮喘患儿随机分为对照组和观察组，各53例。对照组给予沙美特罗替卡松粉吸入剂吸入，观察组加服孟鲁司特钠和脾氨肽冻干粉，疗程均为3个月。治疗前后分别测定患儿外周血白细胞介素-4(IL-4)、干扰素-γ(INF-γ)、肺功能及哮喘控制测试评分(ACT)。结果两组治疗后IL-4均较治疗前明显降低，而INF-γ较治疗前明显升高，且观察组较对照组变化更为明显，差异有统计学意义(P<0.05)。两组治疗后肺功能均较治疗前明显好转， ACT评分均较治疗前明显增高，且观察组较对照组治疗后也有显著的肺功能改善和ACT评分增高，差异有统计学意义(P<0.05)。结论孟鲁司特钠联合脾氨肽能更有效地改善哮喘患儿的肺功能、调节细胞免疫及控制哮喘发作。
目的：觀察孟魯斯特鈉聯閤脾氨肽對哮喘患兒Th1/Th2細胞因子的影響及臨床療效。方法106例支氣管哮喘患兒隨機分為對照組和觀察組，各53例。對照組給予沙美特囉替卡鬆粉吸入劑吸入，觀察組加服孟魯司特鈉和脾氨肽凍榦粉，療程均為3箇月。治療前後分彆測定患兒外週血白細胞介素-4(IL-4)、榦擾素-γ(INF-γ)、肺功能及哮喘控製測試評分(ACT)。結果兩組治療後IL-4均較治療前明顯降低，而INF-γ較治療前明顯升高，且觀察組較對照組變化更為明顯，差異有統計學意義(P<0.05)。兩組治療後肺功能均較治療前明顯好轉， ACT評分均較治療前明顯增高，且觀察組較對照組治療後也有顯著的肺功能改善和ACT評分增高，差異有統計學意義(P<0.05)。結論孟魯司特鈉聯閤脾氨肽能更有效地改善哮喘患兒的肺功能、調節細胞免疫及控製哮喘髮作。
목적：관찰맹로사특납연합비안태대효천환인Th1/Th2세포인자적영향급림상료효。방법106례지기관효천환인수궤분위대조조화관찰조，각53례。대조조급여사미특라체잡송분흡입제흡입，관찰조가복맹로사특납화비안태동간분，료정균위3개월。치료전후분별측정환인외주혈백세포개소-4(IL-4)、간우소-γ(INF-γ)、폐공능급효천공제측시평분(ACT)。결과량조치료후IL-4균교치료전명현강저，이INF-γ교치료전명현승고，차관찰조교대조조변화경위명현，차이유통계학의의(P<0.05)。량조치료후폐공능균교치료전명현호전， ACT평분균교치료전명현증고，차관찰조교대조조치료후야유현저적폐공능개선화ACT평분증고，차이유통계학의의(P<0.05)。결론맹로사특납연합비안태능경유효지개선효천환인적폐공능、조절세포면역급공제효천발작。
Objective To observe the effect of montelukast combined with spleen aminopeptide on peripheral blood Th1/Th2 cytokine in children with asthma and the clinical efficacy.Methods Divided 106 cases of bronchial asthma into control group and observation group with 53 cases in each. The control group were treated with salmeterol and fluticasone propionate powder for inhalation, the observation group were treated with montelukast and spleen aminopeptide oral lyophilized powder on the basis of the control group. Each group patients were treated for 3 months. The level of IL-4, INF-γ in peripheral blood of patients, lung function and the score of ACT(asthma control test) were determined before and after treatment.Results The level of IL-4 was significantly lower in two groups after treatment than that before treatment, the level of INF-γwas higher, and the level of IL-4, INF-γshowed more changes in observation group than in control group, the difference was statistically significant(P<0.05). The lung function in two groups was improved obviously after treatment than that before treatment, the scores of ACT were significantly increased, and the lung function was improved more significantly in the observation group than in the control group and the scores of ACT were significantly increased after treatment, the difference was statistically significant(P<0.05). Conclusion Montelukast combined with spleen aminopeptide can improve the lung function, regulate cell immunity and control asthma more effectively than single salmeterol and fluticasone propionate powder.
